Evidence map›Paper›PMID 31757094›Full record

ReviewJournal of clinical medicine2019

Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs.

Patrizia Leone, Alessio Buonavoglia, Rossella Fasano, Antonio Giovanni Solimando, Valli De Re, Sebastiano Cicco, Angelo Vacca, Vito Racanelli

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Patrizia LeoneDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
Alessio BuonavogliaDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
Rossella FasanoDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
Antonio Giovanni SolimandoDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
Valli De ReBio-Proteomics Facility, Department of Translational Research, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano (PN), Italy.
Sebastiano CiccoDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
Angelo VaccaDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
Vito RacanelliDepartment of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.
University of Bari Aldo Moro · ITCentro di Riferimento Oncologico · ITIstituto Tumori Bari · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 20441 to V.R.
6 · The paper itself

Abstract

One of the hallmarks of cancer is angiogenesis, a series of events leading to the formation of the abnormal vascular network required for tumor growth, development, progression, and metastasis. MicroRNAs (miRNAs) are short, single-stranded, non-coding RNAs whose functions include modulation of the expression of pro- and anti-angiogenic factors and regulation of the function of vascular endothelial cells. Vascular-associated microRNAs can be either pro- or anti-angiogenic. In cancer, miRNA expression levels are deregulated and typically vary during tumor progression. Experimental data indicate that the tumor phenotype can be modified by targeting miRNA expression. Based on these observations, miRNAs may be promising targets for the development of novel anti-angiogenic therapies. This review discusses the role of various miRNAs and their targets in tumor angiogenesis, describes the strategies and challenges of miRNA-based anti-angiogenic therapies and explores the potential use of miRNAs as biomarkers for anti-angiogenic therapy response.

Indexed as

anti-angiogenic therapiesendothelial cellsmicroRNAstumor angiogenesis

Identifiers

PMID31757094
PMCPMC6947031
OpenAlexW2990709965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.